SELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical Development
February 10 2020 - 7:45AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the
“Company”), a late-stage clinical biopharmaceutical company focused
on the development of novel cancer immunotherapies for a broad
range of cancer indications, today announced that Dragan Cicic, MD,
has joined the Company as Senior Vice President, Clinical
Development. Dr. Cicic will oversee the Company’s clinical
development activities. He will report directly to Angelos
Stergiou, MD, ScD h.c., President and Chief Executive Officer of
SELLAS.
“We are pleased to add Dragan’s expertise and experience to
SELLAS at this very exciting time for the Company. Dragan’s
extensive experience in the biopharmaceutical industry, both in the
area of clinical development and especially with
hematology-oncology drug candidates, is a perfect fit for us at
this time of increased clinical activity for our GPS program,
especially as we have just started our registrational Phase 3 study
in acute myeloid leukemia. As we continue to progress GPS through
clinical development, Dragan’s operational and oncology expertise
will undoubtedly be of tremendous value,” said Angelos Stergiou,
MD, ScD h.c.
“It is exciting to join SELLAS at such a pivotal point of the
Company’s evolution,” said Dr. Cicic. “The earlier results of the
GPS studies, across all indications, are extremely encouraging both
as a monotherapy as well as in the combination approach with
checkpoint blockade. I look forward to working closely with
Angelos and the SELLAS team to advance the GPS program through
clinical trials and make this therapy available to patients with
limited treatment options.”
Dr. Cicic joins SELLAS as Senior Vice President, Clinical
Development. Dr. Cicic has 20 years of experience in the
biopharmaceutical industry. Before joining SELLAS, he was a
Senior Vice President, Clinical Lead, at Klus Pharma, a wholly
owned U.S. subsidiary of Kelun, a major China-based multinational
pharmaceutical company with about 30,000 employees worldwide.
At Klus Pharma, Dr. Cicic led the global clinical development of
targeted solid cancer biologicals and was involved in the
development of novel checkpoint inhibitors as well as other
innovative biological and small molecule drug candidates. Prior to
Klus Pharma, Dr. Cicic held senior management positions at Actinium
Pharmaceuticals where he launched key clinical trials, both early
and late stage, in hematologic malignancies, primarily in acute
myeloid leukemia. Dr. Cicic also worked with QED
Technologies, a consulting company focused on life sciences.
He received his medical degree from the University of Belgrade, and
an MBA from the Wharton School of the University of Pennsylvania.
Dr. Cicic also did a Fellowship at Harvard University. Dr. Cicic
has published extensively in the fields of hematologic malignancies
and solid cancers. He is a member of the American Society of
Hematology (ASH).
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company
focused on the development of novel cancer immunotherapeutics for a
broad range of cancer indications. SELLAS’ lead product candidate,
GPS, is licensed from MSKCC and targets the WT1 protein, which is
present in an array of tumor types. GPS has potential as a
monotherapy or in combination to address a broad spectrum of
hematologic malignancies and solid tumor indications. SELLAS’
second product candidate, nelipepimut-S (NPS), is a HER2-directed
cancer immunotherapy with potential for the treatment of patients
with early stage breast cancer with low to intermediate HER2
expression, otherwise known as HER2 1+ or 2+, which includes triple
negative breast cancer patients, following standard of care.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts are
“forward-looking statements,” including those relating to future
events. In some cases, forward-looking statements can be identified
by terminology such as “plan,” “expect,” “anticipate,” “may,”
“might,” “will,” “should,” “project,” “believe,” “estimate,”
“predict,” “potential,” “intend,” or “continue” and other words or
terms of similar meaning. These statements include, without
limitation, statements related to the Company’s plans for further
development of and regulatory plans for GPS. These forward-looking
statements are based on current plans, objectives, estimates,
expectations and intentions, and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with immune-oncology product development
and clinical success thereof, and other risks and uncertainties
affecting SELLAS and its development programs as set forth under
the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K
filed on March 22, 2019 and in its other SEC filings. Other risks
and uncertainties of which SELLAS is not currently aware may also
affect SELLAS’ forward-looking statements and may cause actual
results and the timing of events to differ materially from those
anticipated. The forward-looking statements herein are made only as
of the date hereof. SELLAS undertakes no obligation to update or
supplement any forward-looking statements to reflect actual
results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor ContactsWill O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
Investor RelationsSELLAS Life Sciences Group,
Inc.917-438-4353info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2024 to May 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From May 2023 to May 2024